CARsgen Therapeutics (OTCMKTS:CRTHF) Trading 13.4% Higher – Still a Buy?

CARsgen Therapeutics Holdings Limited (OTCMKTS:CRTHF) shares shot up 13.4% during mid-day trading on Thursday . The company traded as high as $2.16 and last traded at $2.16. 2,300 shares changed hands during mid-day trading, a decline of 24% from the average session volume of 3,025 shares. The stock had previously closed at $1.9050.

CARsgen Therapeutics Stock Up 13.4%

The company has a 50-day simple moving average of $1.90 and a 200 day simple moving average of $1.78.

CARsgen Therapeutics Company Profile

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is developing autologous CAR-T product candidates, including CT053, which targets B-cell maturation antigen that is in pivotal Phase II/III trial for the treatment of relapsed/refractory multiple myeloma; CT041, which targets Claudin 18.2, is in Phase II/III clinical trial for gastric/gastroesophageal junction cancer and pancreatic cancer, as well as in Phase I clinical trial for gastric or pancreatic cancer; CT011, which is in Phase I clinical trial for patients with Glypican-3 positive IIIa hepatocellular carcinoma (HCC); and CT071, that is in Phase I clinical trial which targets G protein-coupled receptor class C group 5 member D for the treatment of R/R MM and relapsed/refractory primary plasma cell leukemia (R/R pPCL).